Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding demand has caused many to wonder if they are indeed the magical solution to ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Dulaglutide injection Semaglutide injection Liraglutide injection In addition to the FDA’s scrutiny of outsourcing facilities and compounders in the GLP-1 space, the FDA has expressed concerns ...

Nationwide research reassures the short-term psychiatric safety of GLP-1 RAs, with no heightened risk observed in patients with psychiatric disorders or obesity. Study: Suicide and suicide attempt ...

Key drugs in this category include Novo Nordisk’s Ozempic (semaglutide) and Wegovy (semaglutide), and Eli Lilly’s Trulicity (dulaglutide) and Zepbound (tirzepatide). Due to their ability to ...

MAPD and Part D plans may also cover GLP-1 receptor agonists like liraglutide (Victoza), semaglutide (Wegovy, Ozempic), and dulaglutide (Trulicity). GLP-1 medications can be expensive and may come ...

The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity (dulaglutide), which is competing head-to-head with Ozempic in the market ...